2019
DOI: 10.1016/j.transproceed.2018.04.088
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy of Direct-acting Antivirals to Improve Clinical Condition, Fibrosis, and Liver Function in Liver Transplant Recipients Infected by Hepatitis C

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
9
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(9 citation statements)
references
References 9 publications
0
9
0
Order By: Relevance
“…However, the patients involved in these studies were not eradicated from HCV viraemia. 33 Indeed, platelet count is a part of the well-validated Baveno-VI criteria of predicting recurrence of oesophageal varices without documenting eradication of HCV viraemia. 34 Our finding extends the clinical utility of platelet count as a predictor for recurrence of oesophageal varices to the post-eradication status.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…However, the patients involved in these studies were not eradicated from HCV viraemia. 33 Indeed, platelet count is a part of the well-validated Baveno-VI criteria of predicting recurrence of oesophageal varices without documenting eradication of HCV viraemia. 34 Our finding extends the clinical utility of platelet count as a predictor for recurrence of oesophageal varices to the post-eradication status.…”
Section: Discussionmentioning
confidence: 99%
“…Previous studies identified platelet count as predictor for recurrence of oesophageal varices in chronic liver disease patients including patients with chronic HCV infection. However, the patients involved in these studies were not eradicated from HCV viraemia 33 . Indeed, platelet count is a part of the well‐validated Baveno‐VI criteria of predicting recurrence of oesophageal varices without documenting eradication of HCV viraemia 34 .…”
Section: Discussionmentioning
confidence: 99%
“…A higher rate of acute rejection was seen in the patients who received DAAs 0-3 months post-LT (27%, n=12), compared to those who received DAAs pre-LT (13%, n=34) and ≥3 months post-LT (8%, n=10). The median time on the waitlist was 7 months (interquartile range, IQR [3][4][5][6][7][8][9][10][11][12]. Median follow-up from liver transplant was 36 months (IQR 21-52).…”
Section: Study Cohort Characteristicsmentioning
confidence: 99%
“…6 DAAs halt HCV's continuous insult on the liver and may improve liver function, potentially reducing the risk for developing de novo HCC. 7,8 However, some studies have suggested DAA administration was associated with increased rates of HCC recurrence after curative treatment of HCC. 9,10 On the other hand, recent larger and well-controlled studies found no significant difference in HCC recurrence in DAAtreated patients, and multi-center studies from both the U.S. and Asia have shown significant survival improvement in HCC patients with HCV cure.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation